214 related articles for article (PubMed ID: 36453088)
1. A comprehensive single cell data analysis of lymphoblastoid cells reveals the role of super-enhancers in maintaining EBV latency.
Yan B; Wang C; Chakravorty S; Zhang Z; Kadadi SD; Zhuang Y; Sirit I; Hu Y; Jung M; Sahoo SS; Wang L; Shao K; Anderson NL; Trujillo-Ochoa JL; Briggs SD; Liu X; Olson MR; Afzali B; Zhao B; Kazemian M
J Med Virol; 2023 Jan; 95(1):e28362. PubMed ID: 36453088
[TBL] [Abstract][Full Text] [Related]
2. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes.
Wang C; Li D; Zhang L; Jiang S; Liang J; Narita Y; Hou I; Zhong Q; Zheng Z; Xiao H; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Jul; 93(13):. PubMed ID: 31019051
[TBL] [Abstract][Full Text] [Related]
3. Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
Messinger JE; Dai J; Stanland LJ; Price AM; Luftig MA
mBio; 2019 Jul; 10(4):. PubMed ID: 31266868
[TBL] [Abstract][Full Text] [Related]
4. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus Episome Physically Interacts with Active Regions of the Host Genome in Lymphoblastoid Cells.
Wang L; Laing J; Yan B; Zhou H; Ke L; Wang C; Narita Y; Zhang Z; Olson MR; Afzali B; Zhao B; Kazemian M
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999023
[TBL] [Abstract][Full Text] [Related]
7. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
8. TAF Family Proteins and MEF2C Are Essential for Epstein-Barr Virus Super-Enhancer Activity.
Wang C; Jiang S; Zhang L; Li D; Liang J; Narita Y; Hou I; Zhong Q; Gewurz BE; Teng M; Zhao B
J Virol; 2019 Aug; 93(16):. PubMed ID: 31167905
[TBL] [Abstract][Full Text] [Related]
9. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
10. Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.
Bristol JA; Brand J; Ohashi M; Eichelberg MR; Casco A; Nelson SE; Hayes M; Romero-Masters JC; Baiu DC; Gumperz JE; Johannsen EC; Dinh HQ; Kenney SC
PLoS Pathog; 2022 Apr; 18(4):e1010453. PubMed ID: 35472072
[TBL] [Abstract][Full Text] [Related]
11. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
Rowe M; Raithatha S; Shannon-Lowe C
J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.
Lin KM; Lin SJ; Lin JH; Lin PY; Teng PL; Wu HE; Yeh TH; Wang YP; Chen MR; Tsai CH
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776277
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
14. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.
Faumont N; Durand-Panteix S; Schlee M; Grömminger S; Schuhmacher M; Hölzel M; Laux G; Mailhammer R; Rosenwald A; Staudt LM; Bornkamm GW; Feuillard J
J Virol; 2009 May; 83(10):5014-27. PubMed ID: 19264782
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome.
Dunn LEM; Lu F; Su C; Lieberman PM; Baines JD
J Virol; 2023 Feb; 97(2):e0189422. PubMed ID: 36744959
[TBL] [Abstract][Full Text] [Related]
16. The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines.
Ding W; Wang C; Narita Y; Wang H; Leong MML; Huang A; Liao Y; Liu X; Okuno Y; Kimura H; Gewurz B; Teng M; Jin S; Sato Y; Zhao B
J Virol; 2022 Sep; 96(18):e0073922. PubMed ID: 36094314
[TBL] [Abstract][Full Text] [Related]
17. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.
Le Clorennec C; Youlyouz-Marfak I; Adriaenssens E; Coll J; Bornkamm GW; Feuillard J
Blood; 2006 Mar; 107(5):2070-8. PubMed ID: 16317104
[TBL] [Abstract][Full Text] [Related]
18. Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells.
Nawandar DM; Ohashi M; Djavadian R; Barlow E; Makielski K; Ali A; Lee D; Lambert PF; Johannsen E; Kenney SC
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179525
[TBL] [Abstract][Full Text] [Related]
19. An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.
Ma SD; Yu X; Mertz JE; Gumperz JE; Reinheim E; Zhou Y; Tang W; Burlingham WJ; Gulley ML; Kenney SC
J Virol; 2012 Aug; 86(15):7976-87. PubMed ID: 22623780
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
